News

We provide the latest news
from the world of economics and finance

05 January

ViewRay gains amid new purchase orders for radiation therapy system

Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration. — JuSun

MRIdian is designed to provide oncologists with diagnostic-quality magnetic resonance imaging, helping them to adapt a radiation therapy to the targeted cancer.

The company said that University Hospitals in Cleveland has entered into a master agreement to immediately purchase one MRIdian system with the option to order additional three systems.

In another agreement, a subsidiary of Shanghai Fosun (OTCPK:SFOSF) unit Chindex Medical Limited has ordered 10 MRIdian systems.

Shanghai Fosun (OTCPK:SFOSF) has been ViewRay’s (VRAY) distribution partner in China, where MRIdian was granted the regulatory nod in September 2022.

Seeking Alpha contributor Zach Bristow upgraded ViewRay (VRAY) to Buy in November citing the company’s revised 2022 guidance.

Share on social media

Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520

Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus

Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details

Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.

Sitemap

Tel: +357 25 055 966

E-mail: 24_support@j2t.com

Trading accounts

Instruments

Platforms

Trading Assistance

Information

Security

News

Risk warning: